TW202033189A - 醫藥學方法 - Google Patents

醫藥學方法 Download PDF

Info

Publication number
TW202033189A
TW202033189A TW108142221A TW108142221A TW202033189A TW 202033189 A TW202033189 A TW 202033189A TW 108142221 A TW108142221 A TW 108142221A TW 108142221 A TW108142221 A TW 108142221A TW 202033189 A TW202033189 A TW 202033189A
Authority
TW
Taiwan
Prior art keywords
cancer
administered
tumor
cell
carcinoma
Prior art date
Application number
TW108142221A
Other languages
English (en)
Chinese (zh)
Inventor
阿洛 Ｎ 麥金
金凡珍
金成哲
朴哲禧
Original Assignee
美商Ｌｓｋ生命伙伴股份有限公司（亦以艾勒華療法公司名義營業）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商Ｌｓｋ生命伙伴股份有限公司（亦以艾勒華療法公司名義營業） filed Critical 美商Ｌｓｋ生命伙伴股份有限公司（亦以艾勒華療法公司名義營業）
Publication of TW202033189A publication Critical patent/TW202033189A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108142221A 2018-11-21 2019-11-20 醫藥學方法 TW202033189A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770437P 2018-11-21 2018-11-21
US62/770,437 2018-11-21

Publications (1)

Publication Number Publication Date
TW202033189A true TW202033189A (zh) 2020-09-16

Family

ID=70774631

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108142221A TW202033189A (zh) 2018-11-21 2019-11-20 醫藥學方法

Country Status (11)

Country Link
US (1) US20230149377A1 (https=)
EP (1) EP3883561A4 (https=)
JP (1) JP2022507686A (https=)
KR (1) KR20210099022A (https=)
AU (1) AU2019384802A1 (https=)
CA (1) CA3120366A1 (https=)
IL (1) IL283273A (https=)
MX (1) MX2021005936A (https=)
SG (1) SG11202105221XA (https=)
TW (1) TW202033189A (https=)
WO (1) WO2020106898A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024137821A1 (en) * 2022-12-21 2024-06-27 Elevar Therapeutics, Inc. Effect of rivoceranib on cytochrome p450 enzyme substrates
WO2025261988A1 (fr) * 2024-06-17 2025-12-26 Assistance Publique Hopitaux De Paris Utilisation de nintédanib pour le traitement de la maladie de castleman

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU2013204181A1 (en) * 2006-11-06 2013-05-16 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
CN101675930B (zh) * 2008-09-16 2012-04-25 江苏恒瑞医药股份有限公司 用于治疗增生性疾病的药物组合物
EP3141245A1 (en) * 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
CN106038566B (zh) * 2016-06-10 2018-11-27 江阴市人民医院 一种用于胃癌治疗的药物组合物及其应用
CN107669685A (zh) * 2016-08-02 2018-02-09 江苏恒瑞医药股份有限公司 阿帕替尼与替加氟和紫杉类药物联合用于制备治疗胃癌的药物中的用途

Also Published As

Publication number Publication date
IL283273A (en) 2021-07-29
KR20210099022A (ko) 2021-08-11
CA3120366A1 (en) 2020-05-28
US20230149377A1 (en) 2023-05-18
WO2020106898A1 (en) 2020-05-28
AU2019384802A1 (en) 2021-06-17
EP3883561A1 (en) 2021-09-29
EP3883561A4 (en) 2022-07-27
MX2021005936A (es) 2021-08-24
JP2022507686A (ja) 2022-01-18
SG11202105221XA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
AU2015329625B2 (en) Synergistic auristatin combinations
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
JP2021046430A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
BR112015023483B1 (pt) Uso de um inibidor de b-raf e um inibidor de mek ½”
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN105120663B (zh) 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物
JP2021502415A (ja) 癌の処置のためのアパチニブを用いる併用療法
TW201839399A (zh) 癌症治療
TW202033189A (zh) 醫藥學方法
CN120379663A (zh) Dcc-3116和mapkap路径抑制剂组合用于治疗病症
CN102770026B (zh) 组合
KR20230116899A (ko) 고형 종양 치료를 위한 krasg12c 억제제 및 egfr-억제제를포함하는 방법 및 조성물
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
CN114787151B (zh) 喹唑啉衍生物或其盐、或其药物组合物的用途
US20250352539A1 (en) Combination therapy for treating cancer
TW202547503A (zh) 於癌症的治療中之ｐｍ１４和拓樸異構酶ｉ抑制劑的組合
WO2025101623A1 (en) Methods of treating cancer
WO2023051606A1 (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
TW202506115A (zh) 一種藥物組合及其應用
WO2024255883A1 (zh) Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
CN117043159A (zh) Kras突变型癌症的治疗
EA053195B1 (ru) Ингибитор kras g12c для лечения рака
CN116265030A (zh) 包含酪氨酸激酶抑制剂德立替尼的药物组合
HK40103356A (zh) Kras突变型癌症的治疗